Icon Plc is a leading global provider of outsourced development and commercialization services to the pharmaceutical, biotechnology, and medical device industries. The company specializes in offering a comprehensive range of services that encompass a wide array of phases in the drug development process, from early-stage research and clinical trials to regulatory submissions and post-market support. With a focus on advancing healthcare innovations, Icon collaborates closely with its clients to optimize their product development strategies, improve operational efficiency, and accelerate the path to market for new therapeutic products. Their expertise encompasses various therapeutic areas, providing tailored solutions that address the specific needs of each client. Read More
Icon (NASDAQ:ICLR) executives used the company’s latest earnings call to address the results of an accounting investigation, outline fourth-quarter and full-year 2025 performance, and provide guidance for 2026 amid what management described as near-term revenue and margin headwinds.
Chief Executive
ICON plc (NASDAQ: ICLR), a world-leading clinical research organization, today reported its financial results for the fourth quarter and full year 2025, and announced the outcome of its investigation by the Audit Committee of the Board of Directors into certain accounting practices.
ICON plc (NASDAQ: ICLR), a world-leading clinical research organization, today announced that it will release financial results for the fourth quarter and full year 2025 results after the market closes on Wednesday, May 27, 2026. The Company will hold a conference call and webcast to discuss its financial results and performance on Thursday, May 28, 2026 at 8:00am ET.
ICON plc (NASDAQ: ICLR), a world-leading clinical research organisation, today announced the expansion of its early phase capabilities with the opening of a new, state-of-the-art Clinical Research Unit (CRU) in San Antonio, Texas, as well as new satellite outpatient clinics in Houston, Texas and Lawrence, Kansas. These new, purpose-built clinics will significantly expand ICON’s capacity to conduct first-in-human, healthy participant, and patient cohort studies.
ICON plc (NASDAQ: ICLR), a world-leading clinical research organization, today announced that the Audit Committee of the Board of Directors has completed its investigation into certain of the Company’s accounting practices and controls.
ICON plc (NASDAQ: ICLR), a world-leading clinical research organisation, and Advarra, the market leader in regulatory reviews and a leading provider of connected, intelligence-powered research technology, have entered a definitive partnership agreement to introduce a new ‘research-ready,’ connected site network model for clinical trials.
NEW YORK, March 16, 2026 (GLOBE NEWSWIRE) -- Lowey Dannenberg P.C., a preeminent law firm in obtaining redress for consumers and investors, is investigating ICON PLC (“ICON” or the “Company”) (NASDAQ: ICLR) for potential violations of the federal securities laws.
NEW YORK, March 03, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of ICON plc (“ICON” or the “Company”) (NASDAQ: ICLR). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
MILWAUKEE, Feb. 26, 2026 (GLOBE NEWSWIRE) -- Ademi LLP is investigating possible securities fraud claims against ICON (NASDAQ: ICLR). The investigation results from inaccurate statements ICON may have made regarding its financial statements, business operations and prospects.
LOS ANGELES, Feb. 25, 2026 (GLOBE NEWSWIRE) -- The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of ICON Public Limited Company (“ICON” or “the Company”) (NASDAQ: ICLR) for violations of the securities laws.
The law firm of Kirby McInerney LLP continues its investigation on behalf of ICON Public Limited Company (“ICON” or the “Company”) (NASDAQ:ICLR) investors concerning the Company’s and/or members of its senior management’s possible violation of the federal securities laws and other unlawful business practices.
NEW YORK, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of ICON plc (“ICON” or the “Company”) (NASDAQ: ICLR). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
NEW YORK, Feb. 19, 2026 (GLOBE NEWSWIRE) -- The law firm of Kirby McInerney LLP reminds investors its investigation on behalf of ICON Public Limited Company (“ICON” or the “Company”) (NASDAQ:ICLR) investors concerning the Company’s and/or members of its senior management’s possible violation of the federal securities laws or other unlawful business practices.
The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of ICON Public Limited Company (“ICON” or “the Company”) (NASDAQ: ICLR) for violations of the securities laws.
Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In ICON (ICLR) To Contact Him Directly To Discuss Their Options
The law firm of Kirby McInerney LLP is investigating potential claims against ICON Public Limited Company (“ICON” or the “Company”) (NASDAQ:ICLR). The investigation concerns whether the Company and/or members of its senior management may have violated federal securities laws or engaged in other unlawful business practices.
Glancy Prongay Wolke & Rotter LLP, a leading national shareholder rights law firm, today announced that it has commenced an investigation on behalf of ICON Public Limited Company (“ICON” or the “Company”) (NASDAQ: ICLR) investors concerning the Company’s possible violations of the federal securities laws.
Law Offices of Howard G. Smith announces an investigation on behalf of ICON Public Limited Company (“ICON” or the “Company”) (NASDAQ: ICLR) investors concerning the Company’s possible violations of federal securities laws.
The Law Offices of Frank R. Cruz announces an investigation of ICON Public Limited Company (“ICON” or the “Company”) (NASDAQ: ICLR) on behalf of investors concerning the Company’s possible violations of federal securities laws.
